Matej Oresic
Ph.D.
matej.oresic@utu.fi +358 29 450 3798 +358 46 923 3395 Tykistökatu 6 Turku |
Systems biology, exposome, bioinformatics, metabolomics, lipidomics, biophysics, systems medicine, computational biology
Professor Matej Orešič holds a PhD in biophysics from Cornell University (1999; Ithaca, NY, USA). He is professor of medicine, with specialization in systems medicine at Örebro University (Sweden) and a professor of biochemistry (metabolomics) at the University of Turku (Finland). Prof. Orešič’s main research areas include exposomics and metabolomics applications in biomedical research and systems medicine. He is particularly interested in the identification of environmental exposures (exposome) and disease processes associated with different metabolic phenotypes and the underlying mechanisms linking these processes with the development of specific disorders or their co-morbidities. Prof. Orešič also initiated the popular MZmine open-source project, which led to the development and release of popular software for metabolomics data processing. As of 2016, he was made a Lifetime Honorary Fellow of the Metabolomics Society. Professor Orešič currently serves as member of the Board of Directors of the Metabolomics Society and is one of the founders of the Nordic Metabolomics Society, previously serving as its chair of the board. In 2019, he co-chaired the 1st Gordon Research Conference on ‘Metabolomics and Human Health’ (Ventura, CA, USA). Previously, he also chaired the Keystone Symposium on Systems Biology of Lipid Metabolism (2015; Breckenridge, CO, USA). Professor Orešič currently coordinates Horizon Europe project “Inflammation in human early life: targeting impacts on life-course health – INITIALISE (https://initialise-project.eu/)”. He is also Co-Coordinator of the new Horizon Europe project “Investigation of endocrine-disrupting chemicals as contributors to progression of metabolic dysfunction-associated steatotic liver disease – EDC-MASLD (https://edc-masld.eu/)”.
Professor Orešič’s main research areas include exposomics and metabolomics applications in biomedical research and systems medicine. He is particularly interested in the identification of environmental exposures (exposome) and disease processes associated with different metabolic phenotypes and the underlying mechanisms linking these processes with the development of specific disorders or their co-morbidities. Prof. Orešič also initiated the popular MZmine open-source project, which led to the development and release of popular software for metabolomics data processing. Professor Orešič currently coordinates Horizon Europe project “Inflammation in human early life: targeting impacts on life-course health – INITIALISE (https://initialise-project.eu/)”. He is also Co-Coordinator of the new Horizon Europe project “Investigation of endocrine-disrupting chemicals as contributors to progression of metabolic dysfunction-associated steatotic liver disease – EDC-MASLD (https://edc-masld.eu/)”.
- Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease (2022)
- JHEP Reports
- Metabolomic and proteomic profiling in bipolar disorder patients revealed potential molecular signatures related to hemostasis (2022)
- Metabolomics
- Multi-omics: Trends and applications in clinical research (2022)
- Frontiers in Molecular Biosciences
- Permutation-based significance analysis reduces the type 1 error rate in bisulfite sequencing data analysis of human umbilical cord blood samples (2022)
- Epigenetics
- Plasma lipid alterations in young adults with psychotic experiences: A study from the Avon Longitudinal Study of Parents and Children cohort (2022)
- Schizophrenia Research
- Quantitative modelling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease (2022)
- iScience
- Serum metabolome associated with severity of acute traumatic brain injury (2022)
- Nature Communications
- The human liver lipidome is significantly related to the lipid composition and aggregation susceptibility of low-density lipoprotein (LDL) particles (2022)
- Atherosclerosis
- Traumatic brain injury: progress and challenges in prevention, clinical care, and research (2022)
- Lancet Neurology
- Umbilical cord blood DNA methylation in children who later develop type 1 diabetes (2022)
- Diabetologia
- 1‐deoxyceramides – key players in lipotoxicity and progression to type 2 diabetes? (2021)
- Acta Physiologica
- Activation of pregnane X receptor induces atherogenic lipids and PCSK9 by a SREBP2-mediated mechanism (2021)
- British Journal of Pharmacology
- Allostatic hypermetabolic response in PGC1 alpha/beta heterozygote mouse despite mitochondrial defects (2021)
- FASEB Journal
- Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis (2021)
- Schizophrenia Bulletin
- Conjugated C-6 hydroxylated bile acids in serum relate to human metabolic health and gut Clostridia species (2021)
- Scientific Reports
- Deep learning meets metabolomics: a methodological perspective (2021)
- Briefings in Bioinformatics
- Dysregulated lipid metabolism precedes onset of psychosis (2021)
- Biological Psychiatry
- Exposure to per- and polyfluoroalkyl substances associates with an altered lipid composition of breast milk (2021)
- Environment International
- Glucosylceramide synthase deficiency in the heart compromises β1-adrenergic receptor trafficking (2021)
- European Heart Journal
- Interpreting the lipidome: bioinformatic approaches to embrace the complexity (2021)
- Metabolomics